Clinical trial Data and Safety Monitoring Boards (DSMBs) have a primary obligation of ensuring study participant safety, while maintaining trial integrity. The role of DSMBs is expanding, and ideally should include post-hoc reporting of deliberative processes related to clinically important safety issues or factors that could impact on future trial designs. We describe how the TOPCAT DSMB detected, investigated, and adjudicated an unexpectedly large renal adverse event signal midway through the trial, and offer general guidelines for dealing with similar unanticipated occurrences in future trials. The detection of a greater than expected incidence of deterioration in renal function, occurring in 6.1% of patients in the spironolactone arm compared with 3.9% in the placebo arm (P = 0.009), led to an in-depth DSMB review of associated study medication withdrawals and adverse events. The trial continued uninterrupted throughout the review, which reached the conclusions that spironolactone-associated renal dysfunction did not compromise overall patient safety or interfere with a perceived efficacy signal. Although no discrete mechanism for the spironolactone-associated renal adverse event signal was identified, likely possibilities are discussed. In clinical trials, DSMBs and co-ordinating centres should have the resources to detect, investigate, and adjudicate unexpected safety issues, with goals of ensuring patient safety and preserving the potential for detection of therapeutic effectiveness. In TOPCAT, spironolactone-associated renal dysfunction emerged as a potentially trial-threatening adverse event and, although clinically important, did not lead to compromise of patient safety, trial interruption, termination, or apparent loss of treatment effectiveness.
Introduction
The first-order responsibility of clinical trial Data and Safety Monitoring Committees/Boards (DSMBs) is 'to protect the safety of trial participants'.
1 DSMBs also play a role in maintaining the integrity of trials, with a broad licence to monitor virtually all trial activities. There is an emerging consensus that transparency should be practised for important clinical trial results and activities. 2, 3 In the 4 it is our position that following trial completion and publication of the primary results, DSMBs should contribute to transparency by reporting findings and deliberations that may impact clinical practice or future trial designs. 5 The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT) 6 was a large multinational National Heart Lung and Blood Institute (NHLBI)-sponsored clinical trial conducted in 233 sites in six countries, which investigated the effects of the mineralocorticoid receptor antagonist (MRA) spironolactone vs. placebo on clinical outcomes in patients with heart failure with preserved left ventricular ejection fraction (HFpEF). We describe herein how routine monthly safety screens and data from a regularly scheduled DSMB meeting triggered an extensive investigation of a renal adverse event (AE) signal, the data investigated, the review process, and the conclusions reached.
Methods

TOPCAT Data and Safety Monitoring Board organization
The organization and responsibilities of the TOPCAT DSMB have been previously described, 7 and the DSMB Charter is included as Supplementary material online. The interim analysis plan developed by the Clinical Trial Coordinating Center (CTCC; New England Research Institutes, Watertown, MA, USA), approved by the Trial's Executive Committee, and conducted by the DSMB, included unblinded evaluations of the data for safety and efficacy after accrual of ∼33, 50, and 75% of the expected number of confirmed primary endpoints.
Data and Safety Monitoring Board pre-specified plan for monitoring renal function and hyperkalaemia in TOPCAT
TOPCAT enrolled its first patient on 10 August 2006. The TOPCAT DSMB pre-specified monthly safety review included serum potassium (K + ) and creatinine (Cr) levels, because of the potential for MRAs 8 and other inhibitors of the renin-angiotensin-aldosterone system (RAAS) to produce hyperkalaemia. Renal dysfunction is a risk factor for hyperkalaemia, and there was also a prior report of worsening renal function (WRF) in an elderly reduced ejection fraction heart failure (HFrEF) population treated with spironolactone. 9 Consequently, at the first scheduled DSMB meeting in December 2006, the DSMB requested monthly reports from the CTCC on four issues related to safety: all-cause mortality, hyperkalaemia, renal failure (defined as ever having serum Cr ≥3.0 mg/dL), and dose reductions or permanent discontinuations of study drug. The data arranged in masked treatment arms were to be reviewed monthly by the DSMB Chair, who would issue an opinion to the NHLBI regarding continuing the trial as designed and conducted.
Results
Detection of a potential renal adverse event signal probably related to spironolactone
Examples of the safety data reported monthly to the DSMB chair are given in Tables 1 and 2 . From the beginning of the trial, monthly safety reports revealed an excess of permanent drug discontinuation in one arm, 'Arm X' (spironolactone) vs. 'Arm Y' (placebo) due to both hyperkalaemia and abnormal renal function (Table 1) . However, the number of discontinued patients was small (12 out of 401 patients, reporting serum Cr increases to ≥3.0 mg/dL was extremely small (3 out of 401, Table 2 ). Assuming a worse case that the excess hyperkalaemia and possible renal adverse effects were in the spironolactone arm, this evidence was interpreted as consistent with the anticipated effects of the MRA drug class. These data  followed the same pattern through 2008 and 2009, as can be  observed in the report of 31 October 2008 (Tables 1 and 2) . As a result, straightforward 'no objection to continuation of the trial' opinions were issued by the DSMB Chair after review of the June 2007 report and for all subsequent reports up to 29 October 2010. By 31 August 2010, the Arm X and Arm Y permanent drug discontinuations for WRF had reached 17% and 8%, respectively, of a total of 51 in 2639 randomized patients, with a serum Cr ≥3.0 mg/dL of 3% and 2%, respectively, for 67 total events. The masking process for mortality re-labelled the treatment arms as Arm 1 and Arm 2 (subsequently identified as spironolactone/placebo), which in the August 2010 report was 4.5% and 6%, respectively, based on 138 deaths. This was a continuation of the trends of previous monthly data, and again a 'no objection' letter was issued. However, it was appreciated that the renal function data might be a harbinger of clinically important serious adverse events (SAEs) if Arm X was also Arm 2.
The closed session of the regularly scheduled DSMB meeting on 27 October 2010 reviewed data through 31 August 2010, and conducted the second unblinded interim efficacy (at 50% of the expected primary events) and safety analysis. As part of the review, a by-treatment arm figure depicting the time to doubling of serum Cr to a level above the limits of normal, the study definition of deterioration in renal function, was presented by the CTCC (Figure 1 ). These data precipitated discussion about further analyses needed to determine if there was a renal dysfunction safety issue. Although there was no statistically significant difference between treatment arms in the number of patients reaching a serum Cr of ≥3.0 mg/dL [37 in Arm 1/spironolactone vs. 31 in Arm 2/placebo (P = 0.46)], or in the time to reach this level (P = 0.48, Figure 2 ), the DSMB asked for a report of all individual renal AEs and SAEs by treatment group, to be subsequently reviewed by the DSMB Chair.
On the subsequent monthly safety report dated 1 November 2010 that included data through 29 October 2010 (Tables 1 and 2), the difference in the number of study drug discontinuations for abnormal renal function continued to widen, and was now 2.4-fold for Arm X vs. Arm Y compared with a 1.5-fold difference 2 years earlier ( Table 1 ). In addition, the percentage of patients reaching a serum Cr of ≥3.0 mg/dL appeared to be demonstrating a trend for Arm X (3%) being higher than Arm Y (2%, Table 2 ). Chair in advance of receipt of the AE/SAE information requested at the October meeting and found again to have no imbalance between blinded treatment groups. Table 3 and all renal/genitourinary AEs including multiple episodes/patient, date of onset, relationship to study drug as assessed by the investigator, investigator-assessed severity, whether the AE was an SAE, and a brief clinical description of the episode were included in the database. The DSMB Chair selected the events that were deemed to be of particular concern as being possibly related to WRF. Table 4 contains a summary of these data. The number of selected renal AEs per patient as well as the number of patients having at least one such AE was ∼2-fold higher in Arm 1 (subsequently identified as spironolactone) vs. Arm 2 (P = 0.009 for the number of patients with any AE), a clear difference but at a low incidence in both arms (3.6% in Arm 1/spironolactone and 1.9% in Arm 2/placebo). The severity of AEs did not differ in the two arms. The overall incidence of selected renal SAEs, similarly two-fold higher in Arm 1 vs. Arm 2 (P = 0.13 for subjects with any SAE), was extremely low at respective incidences of 1.4% and 0.8% per patient. A These data were considered consistent with a signal for renal dysfunction in Arm 1, presumed to be at the time and subsequently confirmed to be spironolactone. The DSMB Chair then requested additional information including: (i) specific morbid AEs or deaths associated with AEs; (ii) SAEs associated with study medication discontinuation; (iii) by-treatment arm analyses of time to event curves for the primary endpoint (time to the composite of cardiovascular mortality, heart failure hospitalization, or aborted cardiac arrest) and composites of all-cause mortality with any hospitalization, cardiovascular hospitalization, or heart failure hospitalization. Table 4 gives the additional renal AE data, provided on 20 December 2010. Hospitalizations, dialysis, or deaths associated with renal AEs were all low frequency and none was statistically significant between treatment arms (AE resulting in hospitalization P = 0.09, other two P values = 1.00).
The study drug discontinuation rate associated with SAEs was extremely low: 7 (0.5%) in Arm 1 and 4 (0.3%) in Arm 2, P = 0.55. Renal AEs within Arm 1 (spironolactone) vs. Arm 2 (placebo) were not accompanied by higher percentages of hospitalization, dialysis, or death. Similarly, compared with the placebo arm, renal SAEs in the spironolactone arm were not associated with a higher percentage of permanent study medication withdrawal ( Table 4 ). All the time to event curves, including all-cause mortality or all-cause hospitalization, demonstrated a lower rate in Arm 1 vs. Arm 2, suggesting that the study drug in Arm 1 was exerting efficacy despite the renal AE signal. The primary endpoint time to event curves had been evaluated in the 27 October 2010 interim analysis, where the conditional power of 90% 
Literature review
Part of the DSMB's review process was to conduct a more extensive literature review to ascertain if there were any pre-clinical or clinical data indicating nephrotoxicity of MRAs or spironolactone specifically. Previous placebo-controlled trials of MRAs in HFrEF 10,11 or post-myocardial infarction LV dysfunction 12 had produced evidence of increased hyperkalaemia but no evidence of adverse effects on renal function, and in one of them 11 patients had a mean age similar to TOPCAT's 69 years. A review of effects of spironolactone in patients with various renal disorders 13 -17 and in pre-clinical renal dysfunction settings 18 -21 produced only evidence of renal-sparing properties, and no evidence of a nephrotoxic mechanism. Thus, at the time of the DSMB renal AE investigation in late 2010, a thorough literature review did not provide cause for concern beyond the previous report in older HFrEF patients 9 known at the beginning of the trial.
Data and Safety Monitoring Board decision
Based on these data and literature review, a provisional no objection to continue the trial letter was delivered by the DSMB Chair to the sponsor on 22 November 2010, in advance of a full meeting of the DSMB. On 3 January 2011 the full DSMB concluded that although there was evidence of a renal AE signal in the presumed spironolactone arm, it did not rise to a level of safety concern, and it did not appear to preclude the opportunity to detect potential beneficial effects of spironolactone. Later that day, the DSMB issued the following statement to the NHLBI: 'After a thorough review of the renal AE issues in TOPCAT, the entire DSMB has no objection to continuing the trial.' One year later, the DSMB Chair conducted a follow-up audit of renal AEs and SAEs, and determined that the patterns were qualitatively unchanged from the data reviewed in November 2010.
Relationship to trial final outcomes
These observations, conducted on the first 77% of the randomized TOPCAT population at ∼50% of the total number of primary events, were consistent with the final trial results. 5 In the 3445 randomized patients in TOPCAT who were followed for a mean of 3.3 years, the incidence of serum Cr doubling to a level above the normal range was 10.2% in the spironolactone arm vs. 7.0% in the placebo arm (P = 0.0008), 5 while there were no significant differences in the number of patients with increases of serum Cr to ≥3.0 mg/dL [89/1722 (5.2%) in the spironolactone arm, 83/1722 in the placebo arm (4.8%, P = 0.64)]. Interestingly, among the 260 TOPCAT patients enrolled in North and South America who experienced doubling in serum Cr (158 in the spironolactone arm and 102 in the placebo arm), mortality rates after creatinine doubling were lower in the spironolactone vs. placebo arms respectively 13.1% vs. 33.2% per 100 patient-years, P <0.001), 22 suggesting that increases in Cr associated with spironolactone may be accompanied by favourable clinical effects compared with Cr increases that occurred on placebo. As previously reported, elevations in serum Cr exhibited regional differences, with patients enrolled in the countries of Russia and Georgia not exhibiting treatment arm differences in doubling of serum Cr 6, 7, 22 or hyperkalaemia. 6, 7 However, patients enrolled in Russia and Georgia did exhibit more of the MRA-associated AEs of gynecomastia in the spironolactone arm compared with the placebo arm. 6, 7 
Discussion
Summary of findings
This report describes the detection, investigation, and adjudication of a potentially clinically harmful and trial-terminating renal AE signal of the MRA spironolactone that had not been evident in previous multicentre placebo-controlled heart failure trials. The detection of an unexpectedly prevalent renal AE signal was the result of intensive monitoring of the incidence of hyperkalaemia or elevations in serum Cr. The subsequent investigation of the renal AE signal resulted in the issuance of a 'no objection' recommendation for continuing the trial. In order to reach this conclusion, the DSMB and the CTCC had to develop convincing evidence of the absence of any clinically significant safety concerns, plus evidence that spironolactone efficacy was not apparently being compromised. The absence of a safety concern was based on: the relatively low incidence of renal AEs in the spironolactone arm (3.6% vs. 1.9% in placebo); no statistically significant difference in renal SAEs (1.4% Arm 1, 0.8% Arm 2); no significant difference in renal AEs resulting in hospitalizations, deaths, or dialysis; and no difference in permanent study drug withdrawals based on renal SAEs. The review process was conducted over a relatively short period of time, and was facilitated by rapid data generation and effective communication among the DSMB, the Sponsor, and the CTCC.
Recent reports of effects of mineralocorticoid receptor antagonists on renal function or renal dysfunction in heart failure with preserved ejection fraction Subsequent to the conduct of TOPCAT, there has been further evidence that prophylactic use of MRAs not only prevents renal dysfunction and histological signs of ischaemia-reperfusion injury, but that MRA administration immediately or shortly after ischaemia-reperfusion injury effectively prevents ischaemic acute kidney injury. 23 Although still controversial, there is also increasing evidence to support the safety and efficacy of MRAs in chronic kidney disease in the setting of careful monitoring for hyperkalaemia. 24, 25 In contrast, in the EMPHASIS trial 26 that investigated mild HFrEF comparing the MRA eplerenone with placebo, there was evidence of renal dysfunction including a statistically significant reduction in estimated glomerular filtration rate (eGFR) by the MRA. As in TOPCAT, there was no interaction of renal AEs with a favourable efficacy signal. 26 There is only very limited information on renal outcomes in the HFpEF patient population. In HFpEF patients hospitalized for decompensated heart failure, Rusinaru et al. 27 reported a WRF rate of 12%, whereas Sharma et al. 28 found a WRF rate of 40%. In the latter study, WRF was associated with higher blood pressure and less fluid removal, but was not associated with differences in clinical outcomes. 28 However, there is recent evidence that renal failure is an important co-morbidity contributing to HFpEF hospitalizations. 
Potential mechanism of mineralocorticoid receptor antagonist-associated elevations in serum creatinine in heart failure with preserved ejection fraction
The cause of WRF in HFpEF patients taking MRAs, particularly in light of the growing body of evidence supporting renal protective effects of this drug class, are unclear. However, there are a few possible mechanisms to consider. In the limited data available on renal outcomes in HFpEF, it appears that blood pressure and fluid overload status are associated with the development of worsening renal failure. 28 Volume shifts in the renal and splanchnic circulatory beds in the setting of fluid overload treatment with diuretics may result in impaired renovascular perfusion, 30 and the abnormally steep pressure-volume relationship in HFpEF patients may make them particularly susceptible to reductions in preload. In heart failure, low dose MRAs have diuretic effects, 31 and so a reduction in cardiac output and blood pressure related to preload reduction in susceptible patients is one possibility. However, a review of events associated with renal dysfunction AEs in TOPCAT did not detect an excess of episodes of volume depletion in the spironolactone arm. Patients with impaired renal autoregulation at baseline may be more susceptible to developing worsening renal failure in the setting of receiving MRAs and/or other antihypertensive agents, resulting in lowering of blood pressure within 'normal' ranges. 32 In TOPCAT, blood pressures were not different at trial entry between the two study groups (Table 3) , and compared with placebo the spironolactone arm exhibited only slight average reductions in both systolic (by 2.7 mmHg compared with 0.2 mmHg in the placebo arm, P <0.001) and diastolic (spironolactone arm by 2.0 mmHg, placebo 0.6 mmHg, P <0.001) pressures. 5 However, blood pressure changes in individual patients have not been analysed in TOPCAT beyond the review of information in the renal AE reports.
Finally, patients in TOPCAT were on relatively high doses of ACE inhibitors or ARBs. Both agents interfere with renal blood flow autoregulation, and may decrease eGFR in association with decreases in blood pressure. 32 Administration of inhibitors of the RAAS have previously been associated with WRF in HFpEF patients compared with placebo in the I-Preserve trial (8% for the ARB irbesartan vs. 4% on placebo).
33
Conclusions
Potential evidence of an AE signal in multicentre trials, including those that are either unprecedented or unexpected in degree, should precipitate vigorous investigatory responses by the responsible DSMB working with the clinical trial co-ordinating centre. The adjudication should include both patient safety considerations as well as an assessment of the impact on effectiveness of the tested intervention, and in order for a trial to be allowed to continue as designed neither safety nor effectiveness should be importantly compromised.
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